Evidence map›Paper›PMID 35698159›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Fast detection, a precise and sensitive diagnostic agent for breast cancer.

Qiong Wu, Chanling Yuan, Ningzhi Liu, Jing Shu, Jiacheng Wang, Jiayi Qian, Liang Zeng, Hao Zhang, Xicheng Wang, Wenjie Mei

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. A target-activated AS1411 aptamer probe forFrontiers in bioengineering and biotechnology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Qiong WuSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Chanling YuanSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Ningzhi LiuSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Jing ShuSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Jiacheng WangSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Jiayi QianSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Liang ZengDepartment of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. zlxx03@126.com.
Hao ZhangThe First Affiliation Hospital of Guangdong Pharmaceutical University, Guangzhou, 510062, China.
Xicheng WangThe First Affiliation Hospital of Guangdong Pharmaceutical University, Guangzhou, 510062, China. 13902400598@126.com.
Wenjie MeiSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China. wenjiemei@gdpu.edu.cn.
Guangdong Pharmaceutical University · CNFirst Affiliated Hospital of Guangdong Pharmaceutical University · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer targeting diagnostic agent with effective imaging ability is important in guiding plan formulation, prediction, and curative effect evaluation of tumors in clinic. A tumor-targeting nanoprobe based on the functional and programmable Liquid-Liquid phase separation of AS1411 promoted by Ru(II) complex RuPEP may develop into a potential phosphorescence probe to detect breast cancer cells, where AS1411 act as a tumor-targeting guidance moiety to distinguish tumor cells from normal cells and RuPEP act as a light-emitting element to highlight breast cancer cells.

methodsHere we designed and constructed a nanoprobe AS1411@RuPEP, and the physicochemical and biochemical properties were characterized by TEM, AFM and EDS. The breast cancer targeting diagnostic capacity was evaluated by normal/tumor cell co-culture assay, tumor cells targeting tracking in xenograft model and cancerous area selectively distinguishing in human patient tissue.

resultsFurther studies indicated that the nanoprobe exhibits excellent tumor-targeting imaging ability in vitro and in vivo by effectively recognize the over-expressed nucleolin (NCL) on the breast cancer cells membrane. Intriguingly, we discovered that the selectively enrichment of nanoprobe particles in tumor cells is related to ATP-dependent NCL transport processes that rely on the AS1411 component of nanoprobe to recognize NCL. Furthermore, preferential accumulation of nanoprobe is clearly differentiating the human breast cancer tissue surrounding non-cancerous tissue in histological analysis.

conclusionThis study produce a potent nanoprobe can be used as a convenient tool to highlight and distinguish tumor cells in vivo, and indicate the tumorous grading and staging in human breast cancer patient pathological section, which provides an effective way for breast cancer diagnostic imaging by targeting recognize NCL.

Indexed as

Breast NeoplasmsCell Line, TumorFemaleHumansOligodeoxyribonucleotidesOligodeoxyribonucleotidesAS1411Breast cancerNCLTumor-targeting imaging

Identifiers

PMID35698159
PMCPMC9190138
OpenAlexW4282576805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.